Objectives:

As a result of this educational regularly scheduled series, learners as members of the healthcare team will be able to:

  1. Summarize the role of adjuvant PARP inhibitors for early breast cancer with germline BRCA mutations
  2. Discuss the use of checkpoint inhibition in the treatment of early-stage TNBCidentify appropriate options for treatment of recurrent VTE in cancer patients.
  3. Identify appropriate options for treatment of recurrent VTE in cancer patients.
  4. Identify treatment options for aromatase inhibitor associated musculoskeletal symptoms.
  5. Improve communication regarding performance status for older patients with advanced cancer.

***This session will VIRTUAL via zoom*** 

Zoom info:

Join from a PC, Mac, iPad, iPhone or Android device:

    Please click this URL to join. https://uwmadison.zoom.us/s/92122533309?pwd=TTJGYm53V2NJS1BRc2JZK3BFa2c5Zz09

    Passcode: UWCCC

  Or One tap mobile:

    +13017158592,,92122533309# US (Washington DC)

    +13126266799,,92122533309# US (Chicago)

Or join by phone:

    Dial(for higher quality, dial a number based on your current location):

        US: +1 301 715 8592  or +1 312 626 6799  or +1 929 205 6099  or +1 253 215 8782  or +1 346 248 7799  or +1 669 900 6833

    Webinar ID: 921 2253 3309

    International numbers available: https://uwmadison.zoom.us/u/aeaTikRdJQ

Session date: 
Wednesday, September 8, 2021 - 8:00am to 9:00am
Location: 
Health Sciences Learning Center, #1306 Lecture Hall
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™

Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Dr. Meaghan Trainor
Dr. Marina Sharifi